PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma.
The stocks founds in the One Hot Stock category use stocks that are in long term, short term trends and are early in the buy signal trend. Suggested buy prices are listed with a price “or better”. Or better means anything lower than the buy price listed. (Learn about order types here). This is a confirmation strategy that waits for the stock to make a move then a trader enters the trend at specific prices. In many cases stocks that are in up trends tend to continue the overall trend direction and the prior trend is the path of least resistance. To learn more about trend following as well as reversal strategies you can go here.
